Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 10, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-12-02
DOI
10.1186/s13045-017-0541-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EGFR TKI combination with immunotherapy in non-small cell lung cancer
- (2017) Myung-Ju Ahn et al. Expert Opinion On Drug Safety
- Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma
- (2017) Alexandra E. Foran et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
- (2017) Arjun V Balar et al. LANCET
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer
- (2017) Yusuke Okuma et al. LUNG CANCER
- Blinatumomab for Acute Lymphoblastic Leukemia
- (2017) NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
- (2017) Scott J. Antonia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
- (2017) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy
- (2016) Kefang Liu et al. CELL RESEARCH
- Nivolumab in the Treatment of Hodgkin Lymphoma
- (2016) Stephen M. Ansell CLINICAL CANCER RESEARCH
- An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies
- (2016) Julia A. Beaver et al. CLINICAL CANCER RESEARCH
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
- (2016) Brant A. Inman et al. CLINICAL CANCER RESEARCH
- Emerging biomarkers as predictors to anti-PD1/PD-L1 therapies in advanced melanoma
- (2016) Kimberly Loo et al. Immunotherapy
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2016) Naiyer A. Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma
- (2016) Adil I. Daud et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
- (2016) Christophe Massard et al. JOURNAL OF CLINICAL ONCOLOGY
- Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance
- (2016) Kuo-Hsing Chen et al. Journal of Hematology & Oncology
- Programmed cell death-1 blockade in recurrent disseminated Ewing sarcoma
- (2016) Georgia J. B. McCaughan et al. Journal of Hematology & Oncology
- High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy
- (2016) Lorenzo Falchi et al. Journal of Hematology & Oncology
- Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial
- (2016) Qing Zhou et al. Journal of Hematology & Oncology
- Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
- (2016) Shuhang Wang et al. Journal of Hematology & Oncology
- Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy
- (2016) Weijie Ma et al. Journal of Hematology & Oncology
- Immune biomarkers of treatment failure for a patient on a phase I clinical trial of pembrolizumab plus radiotherapy
- (2016) Gregory S. Alexander et al. Journal of Hematology & Oncology
- Emerging therapeutic agents for lung cancer
- (2016) Bhagirathbhai Dholaria et al. Journal of Hematology & Oncology
- 57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC
- (2016) D.L. Gibbons et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Anti-PD-L1 inhibitor durvalumab in bladder cancer
- (2016) Vicki Brower LANCET ONCOLOGY
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Atezolizumab effective against advanced disease
- (2016) Peter Sidaway Nature Reviews Clinical Oncology
- Atezolizumab: an alternative to cisplatin?
- (2016) Peter Sidaway Nature Reviews Clinical Oncology
- Atezolizumab effective against advanced-stage disease
- (2016) Peter Sidaway Nature Reviews Urology
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Mechanisms of resistance to third-generation EGFR tyrosine kinase inhibitors
- (2016) Shuhang Wang et al. Frontiers of Medicine
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab
- (2015) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade
- (2015) Gaurav Goel et al. Journal of Hematology & Oncology
- Nivolumab plus ipilimumab in the treatment of advanced melanoma
- (2015) Katy K. Tsai et al. Journal of Hematology & Oncology
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
- (2015) Jan A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
- (2015) Jie Zhang et al. Thoracic Cancer
- Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies
- (2015) Peter B. Alexander et al. Frontiers of Medicine
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
- (2014) D Rossille et al. LEUKEMIA
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer
- (2014) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
- (2013) Alice T. Shaw et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
- (2011) X. Frigola et al. CLINICAL CANCER RESEARCH
- Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
- (2011) Yongjing Chen et al. CYTOKINE
- US FDA perspective on challenges in co-developingin vitrocompanion diagnostics and targeted cancer therapeutics
- (2011) Reena Philip et al. Bioanalysis
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started